P98 A SIMPLIFIED METHOD OF DETERMINING SYNOVIAL FLUID CHONDROITIN SULFATE CHAIN LENGTH  by Brown, M.P. et al.
S64 Poster Presentations
P97 – Table 1. Concentrations in SF and serum of SHAP, HA, IL-8 and MMP-3. Values are median (25th-75th percentiles)
REF PPA INJ POA
SHAP serumng/mL 7.2 (6.5-9.5) 15.0 (9.3-26.5) 11.5 (8.7-15.6) 10.5 (8.0-13.6)
SHAP SFng/mL 3243 (1723-5965) 37031 (17163-56600) 6211 (2939-14442) 10910 (2415-20045)
HA serumng/mL 47 (31-61) 32 (29-61) 36 (28-48) 39 (28-44)
HA SFμg/mL 1515 (1442-2327) 500 (325-719) 1604 (672-2891) 2539 (1309-5741)
IL-8 serumpg/mL 11.2 (8.7-31.8) 289 (48.2-6062) 26.3 (5.9-193) 25.2 (5.3-217)
IL-8 SFpg/mL 2.1 (0.1-14.4) 26.9 (24.0-140) 2.6 (0.48-15.6) 2.8 (0.04-14.4)
MMP-3 SFng/mL 808 (776-1315) 12430 (3427-52195) 1298 (423-3640) 3355 (1133-12760)
MMP-3 serumng/mL 28 (22-77) 61 (33-143) 33 (22-44) 50 (30-88)
The CXC chemokine interleukin 8 (IL-8), a potent neutrophil
recruiting and activating factor, is a pro-inflammatory cytokine
present in many disease conditions. Matrix metalloproteinase-3
(MMP-3) synthesis and secretion in chondrocytes and synovial
cells is upregulated by inflammation. We determined levels of
SHAP, HA, IL-8 and MMP-3 in synovial fluid (SF) and serum
from patients with OA, inflammatory arthritis and joint injury.
Methods: Paired knee SF and serum samples were from a con-
venience sample of patients with primary knee OA (POA n=43,
mean age 49), knee injury (INJ n=212, mean age 34), pseu-
dogout (PPA n=10, mean age 38), and knee-healthy persons
(n=8, mean age 30). SHAP and HA were quantified by ELISAs,
using plates coated with HA-binding region of bovine aggrecan.
MMP-3 protein was assayed by ELISA. IL-8 was quantified by
LINCO human cytokine multiplex kit (HCYTO-60K-PMX22, and
HCYTO-60K-PMX21).
Results: Group median levels of SHAP in SF were 500-2500
times higher than those in serum, with overall levels highest in
pseudogout (p<0.001, Table 1). The amount of SHAP relative
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to HA was higher in serum than in SF. SHAP levels in SF
were highly correlated with MMP-3 protein (R=0.7, p<0.001, Fig.
1). IL-8 levels correlated with SHAP (R=0.44, p<0.001, Fig. 2)
and MMP-3 (R=0.40, p<0.001). HA levels in SF were low in
pseudogout, normal or high in OA. SHAP concentrations in SF
were elevated for 3 months after knee injuries that commonly
lead to OA, while HA levels were low (p<0.005).
Conclusions: We find very high concentrations of SHAP in
synovial fluid, suggesting local production in the joint. Concen-
trations of SHAP in joint fluid were highly correlated with MMP-3
and IL-8, suggesting synovial activation in joint injury and OA,
as well as in arthritis. In contrast to some previous reports, HA
levels in OA joints were normal or high, compared to those in
healthy knee joints. The observed changes of these potential
biomarkers are consistent with an upregulation of inflammation
after joint injury and in OA.
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Purpose: Concentration, isomer composition, and immunoreac-
tivity of glycosaminoglycans (GAGs), such as chondroitin sulfate
(CS) have been widely studied as biomarkers to monitor changes
in the metabolism of joints. We have shown previously, by se-
quential use of gel filtration chromatography (Superose 6) and
fluorophore-assisted carbohydrate electrophoresis (FACE), that
CS chains in synovial fluid of injured joints are significantly longer
than those in normal joints. FACE is a technique that requires
specialized laboratory equipment and a high level of technical
expertise. Additionally, FACE technique is much more expen-
sive in terms of materials and time per sample. The aim of the
present study was to determine whether dimethylmethylene blue
(DMMB) analysis could be done instead of FACE to determine
CS chain length in synovial fluid.
Methods: Synovial fluid was obtained from carpal joints of: (1)
8 normal Thoroughbred horses after 8 weeks rest, (2) the same
horses after 9 months treadmill training, and (3) 7 Thoroughbred
horses with osteochondral (OC) injury from racing. Superose 6
chromatography and FACE analysis had previously been per-
formed on these samples. Aliquots (250 ul) of the same synovial
fluids were digested in proteinase K, filtered, and then eluted
on a Superose 6 column. Column effluent was collected in 1
ml fractions. Fractions 1 through 13 were discarded; fractions
14 through 23 were collected and analyzed. Our previous work
has shown that the sulfated GAG contained in these fractions is
chondroitin sulfate. DMMB was performed by modification of the
Blyscan method (Biocolor, Accurate Chemical Supplies, West-
bury, NY), adapted to a 384-well microplate technique. Data from
each fraction of each sample was compared between the 2 as-
say methods by Wilcoxon matched-pairs signed-ranks test, with
P>0.05 considered significant.
Results: Sulfated GAG from synovial fluid was quantitated in
ug/ml of fluid by DMMB, according to fragment size. Figure 1A
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shows synovial fluid CS content of the 3 groups as determined
by DMMB. For comparison, Figure 1B shows total sulfated chon-
droitin disaccharide (delta di6S and delta di4S) for the same
samples determined by FACE. For both methods, CS peak oc-
curs at fraction 18 in synovial fluid from joints with OC injury.
Similarly, CS in synovial fluid from exercised joints peaks in frac-
tion 19 with both assays. CS in synovial fluid from rested joints
peaks in fraction 19 when determined by DMMB, but peaks in
fraction 20 when measured by FACE. When ug/ml amounts of
CS for each data point were compared between assays, results
for exercised (n=80) and OC injury joints (n=70) were signifi-
cantly different (P<0.0001), but results for rested joints (n=80)
were not (P=0.92).
Conclusions: When used for quantitation of sulfated CS in syn-
ovial fluid (ug/ml), DMMB gave results that were significantly
different than those from FACE. DMMB may be measuring other
sGAGs in addition to CS. However, when performed after Su-
perose 6 chromatography, DMMB assay appears to discriminate
the longer CS chains in synovial fluid from OC injured joints from
the shorter chains seen in normal joints. Thus, for the specific
purposes of determination of CS chain length, the more simple,
less expensive DMMB assay may be a replacement for FACE
assay. Use of a 384-well microplate allowed use of low volumes
of DMMB reagents. This facilitated quantitation of small amounts
of CS in fractions collected from Superose 6 chromatography.
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Purpose: Adipocytokines resistin and adiponectin are the major
members of adipose tissue-derived peptides, which have been
suggested as a link between insulin resistance, diabetes, and
obesity. Recent data provided also body of evidence on the
implication of adipocytokines in the inflammation, immune re-
sponse, and tissue destruction. This study was undertaken to
examine the (patho)physiological role of resistin and adiponectin
in matched serum and synovial fluid samples from patients with
rheumatoid arthritis (RA) and osteoarthritis (OA).
Methods: Blood and synovial fluid samples from 20 RA and 20
OA patients were analyzed for resistin and adiponectin (ELISA,
Biovendor). The clinical activity of patients with OA and RA
was assessed according to the Western Ontario and McMaster
Universities (WOMAC) index and the 28 joint count Disease
Activity Score (DAS28), respectively.
Results: Serum resistin levels were significantly lower in OA
compared to RA patients (p=0.002), however the levels of
adiponectin in those patients were comparable (p=0.38).
The levels of both adipocytokines in synovial fluid were signifi-
cantly lower in OA than in RA patients (p<0.001). Adiponectin
concentration was lower in synovial fuid than that in systemic
circulation in both diseases. However, in contrast to OA patients,
resistin levels were significantly higher in synovial fluid than in
systemic circulation in RA patients. In RA patients, increased
serum resistin correlated positively with CRP (r=0.53, p<0.02)
and DAS28 (r=0.44, p<0.05), and adiponectin correlated nega-
tively with leukocyte count in synovial fluid (r= -0.45, p<0.05).
No such correlation was observed in OA patients.
Conclusions: The local up-regulation of adipocytokines in RA
synovial fluid points to a possible role of these molecules in
the pathophysiology of inflammatory joint diseases such as RA
rather than OA.
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Purpose: Aggrecan is the major proteoglycan in articular carti-
lage, and is degraded and released from the extracellular matrix
in pathological joint debilitating diseases like osteoarthritis (OA).
The aggrecanases, ADAMTS-4 and ADAMTS-5, and an array
of Matrix Metallo Proteinases (MMPs) are up-regulated in os-
teoarthritis (OA). The aim of the current study was to monitor the
aggrecanase and MMP mediated turnover of aggrecan in human
OA cartilage in response to different cytokines.
Methods: Articular cartilage was obtained from OA patients,
who had undergone total knee arthroplasty. Articular cartilage
was cultured for 21 days with refreshment of medium every 3rd
day in the presence of 100 ng/mL Interleukin-1 alpha (IL-1α)
or 10 ng/ml Oncostatin M (OSM) + 20 ng/mL Tumour Necro-
sis Factor alpha (OSM/TNFα) to stimulate cartilage degradation.
As negative control, explants without cytokine stimulation were
